✦ LIBER ✦

PSS4 Evidence-Based Budgetary Impact Analysis of Ustekinumab in a Health Plan with Moderate-to-Severe Plaque Psoriasis Patients 2

✍ Scribed by Martin, S.; Carter, C.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PSS10 COST PER RESPONDER OF USTEKINUMAB

✍ SR Feldman; M Augustin; S Martin; P Szapary; B Schenkel 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Cost Utility Analysis Based on a Head-to

✍ Feng Pan; Nicole C. Brazier; Neil H. Shear; Farah Jivraj; Brad Schenkel; Ruth Br 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 506 KB

Impact of ustekinumab on health-related

✍ Hidemi NAKAGAWA; Brad SCHENKEL; Mai KATO; Takeshi KATO; Atsuyuki IGARASHI; The J 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 French ⚖ 317 KB

Efficacy and safety of ustekinumab in Ja

✍ Atsuyuki IGARASHI; Takeshi KATO; Mai KATO; Michael SONG; Hidemi NAKAGAWA; THE JA 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 462 KB

Ustekinumab improves overall skin respon

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 47 KB

PSS20 MEDIATION MODELING AND MEASUREMENT

✍ C. Mamolo; A.G. Bushmakin; J.C. Cappelleri; M. Stewart 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB